# BPC-157 FAQ — The Prescription History, FDA Ruling, and Research Status

> Frequently asked questions about BPC-157: the 2023 FDA 503A Category 2 ruling, whether it can be prescribed, what the research shows, WADA status, and what PL 14736 means.

The regulatory history, the science, and the current status — answered directly from the published record.

## Was BPC-157 ever legally prescribed in the United States, and what changed in 2023?

Before September 2023, BPC-157 occupied a regulatory gray area in the US. It was not FDA-approved for any indication, but it also was not explicitly prohibited for compounding pharmacies operating under Section 503A of the Federal Food, Drug & Cosmetic Act — a provision that permits licensed pharmacies to compound customized preparations for individual patients based on valid prescriptions. Some physicians with prescribing authority were ordering it; some compounding pharmacies were preparing it.

On September 29, 2023, the FDA formally classified BPC-157 as a Category 2 bulk drug substance under the 503A Interim Policy. Category 2 means the FDA has identified significant safety risks. The classification simultaneously closed both the 503A channel (individual-prescription pharmacies) and the 503B channel (larger outsourcing facilities). After that date, the legal pathway for BPC-157 to be prescribed and compounded in the United States effectively closed. [14]

## Why did the FDA remove BPC-157 from the 503A compounding list?

The FDA cited three categories of concern in the Category 2 designation: significant safety risks (including potential immune reactions), manufacturing impurity concerns, and insufficient human safety and efficacy data submitted for Category 1 consideration. The agency's assessment was that the existing evidence base — predominantly rodent pharmacology from a single research group, with minimal independent replication and extremely limited human clinical data — did not meet the standard for permitting compounding under 503A. [14]

The only pathway to restore 503A compounding eligibility would be reclassification to Category 1, which requires stakeholders to submit rigorous safety, efficacy, and manufacturing data to the FDA's Pharmacy Compounding Advisory Committee (PCAC). As of 2025, no such submission has produced a reclassification.

## Can BPC-157 still be used in research protocols or clinical studies after the 2023 FDA action?

Yes, within specific regulatory frameworks. The September 2023 Category 2 designation closed the prescription/compounding channel, not the research channel. Research administration of BPC-157 in human subjects can proceed under IRB-approved institutional protocols and, more formally, under FDA-regulated Investigational New Drug (IND) applications. As of 2025, no active, publicly registered IND for BPC-157 in humans is known to be on record. The 2025 intravenous safety pilot (two healthy adults, up to 20 mg IV) represents the most recent published human research, though the institutional framework under which it was conducted was not described in detail in the available literature. [16]

## What does the published research actually show about BPC-157's effects on tendon, gut, and tissue healing?

The animal literature is extensive and consistently positive. In tendon healing, BPC-157 at 10 μg/kg to 10 pg/kg produced functional Achilles tendon-to-bone reattachment in a rat model where spontaneous healing did not occur, and reversed corticosteroid-induced healing impairment [1]. In gut healing, it achieved two to three times higher anastomotic strength before leakage across four bowel anastomosis types in rats [8], and antagonized NSAID-induced gastrointestinal and hepatic damage [7]. In general wound healing, it accelerated closure across skin, muscle, tendon, ligament, bone, and cornea in multiple rat models, with gene upregulation (Akt1, VEGFA, Nos3, MAPK) occurring within 2–10 minutes of application [6].

The consistency of positive outcomes across every published study is itself a data point worth noting — independent reviewers have flagged it as suggestive of publication bias. No published study of BPC-157 has reported null or negative results. [15]

## How many human clinical studies of BPC-157 exist and what did they find?

Three small published human studies exist as of 2025, plus one Phase 2 clinical trial whose full efficacy dataset has not been published in peer-reviewed form.

The Phase 2 trial of PL 14736 (BPC-157) for ulcerative colitis, conducted by Pliva in Croatia, established favorable safety with no adverse events and no lethal dose identified in toxicology work, but efficacy data were not comprehensively published [14]. A 2024 pilot in 12 interstitial cystitis patients showed 80–100% symptom resolution at 6 weeks via intravesicular administration with no adverse events [15]. A 2025 intravenous safety pilot in 2 healthy adults dosed up to 20 mg showed no adverse events, no significant changes in any organ-system laboratory values, and plasma clearance within 24 hours [16]. An additional retrospective study of 16 patients who received intraarticular BPC-157 (alone or with TB-500) for knee pain reported 87.5% pain reduction; this is described in the McGuire et al. 2025 review [15] but was not available as a primary published study in the reviewed literature.

## What are the common doses used in BPC-157 animal research, and how do they translate to human research contexts?

The most common rodent dose is 10 μg/kg/day intraperitoneally. Lower doses of 10 ng/kg and 10 pg/kg are also frequently studied, with published outcomes described as comparable. The full range runs from picogram to microgram per kilogram per day — an unusual span for a bioactive peptide.

Translating animal doses to human research contexts requires careful acknowledgment of species-specific pharmacokinetics, route differences (intraperitoneal is not a standard human route), and the absence of formal human PK data. The only human PK data available come from the 2025 IV pilot, which found plasma clearance within 24 hours at 20 mg IV — consistent with a half-life under 30 minutes [16]. Without established human bioavailability data across routes, any translation from rodent doses to human research contexts involves substantial uncertainty. This site does not propose specific human doses.

## What is BPC-157's mechanism of action?

BPC-157 activates multiple overlapping intracellular repair pathways simultaneously. The primary mechanisms identified across published studies include: VEGFR2-Akt-eNOS axis activation (driving angiogenesis and vascular repair); ERK1/2 MAPK signaling (driving fibroblast proliferation, migration, and wound closure); JAK2-STAT signaling via growth hormone receptor upregulation in fibroblasts (amplifying the tissue response to endogenous GH) [2]; and context-dependent modulation of nitric oxide production [17]. The angiogenesis regulation appears bidirectional — promoting vascular growth in ischemic tissue while opposing pathological neovascularization in corneal injury models — a property that distinguishes it from simple pro-angiogenic growth factors. Src kinase-caveolin-1 cytoprotection and FAK-paxillin signaling in tendon tissue are also described in the literature. The net effect described across studies is a pleiotropic organ protection profile spanning gastrointestinal mucosa, musculoskeletal connective tissue, the cardiovascular system, and the central nervous system.

## Is BPC-157 a prohibited substance for athletes?

Yes. BPC-157 is listed on the World Anti-Doping Agency (WADA) Prohibited List under the S0 category — Non-Approved Substances. S0 covers any pharmacological substance not approved by any governmental regulatory authority for human therapeutic use. Competitive athletes in any WADA-regulated sport who use BPC-157 risk an anti-doping rule violation, regardless of how the compound was obtained or whether it was obtained through a prescription channel that predated the 2023 FDA action. WADA S0 status is independent of FDA compounding classification; it applies globally to any athlete subject to anti-doping rules.

## What is the difference between BPC-157 and its clinical designation PL 14736?

PL 14736 (also PLD-116 and the commercial name bepecin) is the pharmaceutical development designation assigned to BPC-157 by Pliva, the Croatian pharmaceutical company that sponsored the Phase 2 ulcerative colitis trial. The designations refer to the same 15-amino-acid peptide with the same sequence (GEPPPGKPADDAGLV) — PL 14736 is simply the IND-registration and clinical-trial name under which the compound entered human clinical evaluation in Croatia in the early 2000s.

The PL 14736 Phase 2 trial established the human safety record that exists in the literature [14], and it is the most structured human clinical experience with BPC-157. The Pliva program did not proceed to Phase 3, and the full efficacy dataset was not comprehensively published in peer-reviewed literature, which is why the compound's clinical evidence base remains limited despite having reached Phase 2 evaluation more than two decades ago.

## What are the main limitations of the BPC-157 research literature?

The independent 2025 McGuire et al. narrative review — the first review by authors not affiliated with the Zagreb research group — identified four major limitations [15]:

1. **Single-group dominance.** The overwhelming majority of published BPC-157 research originates from a single team at the University of Zagreb (Sikiric, Seiwerth, and colleagues). Independent replication by external laboratories is limited, which affects confidence in reproducibility.

2. **Publication bias.** No published study has reported null or negative results. The complete absence of non-positive findings in a literature spanning three decades is statistically unusual and suggests that negative or inconclusive studies may exist but remain unpublished.

3. **Minimal human data.** Three small human studies totaling approximately 30 subjects do not constitute an adequate evidence base for clinical confidence. The Phase 2 UC trial safety data are encouraging but efficacy data were not comprehensively published.

4. **Route-biology gap.** The most common animal route (intraperitoneal injection) does not correspond to any standard human clinical administration route, complicating translation even at the level of study design.

## What theoretical safety concerns exist for BPC-157?

The theoretical safety concerns cited in the literature and the FDA's Category 2 rationale include: potential immune reactions (the peptide is a foreign structure that could trigger antibody responses with repeated administration); manufacturing impurity concerns (no standardized purity specifications exist for research-grade preparations); potential for pathological angiogenesis at supraphysiological doses (though published evidence suggests BPC-157 inhibits rather than promotes uncontrolled tumor-associated neovascularization [17]); proline metabolite superoxide production; NO overproduction affecting CYP enzyme activity and heme insertion; and theoretical neurodegenerative risk at supraphysiologic NO concentrations. All three published human studies reported no adverse events, and the Phase 2 UC trial found no lethal dose in toxicology work, but the sample sizes involved are too small to characterize rare adverse event rates.

## Can doctors prescribe BPC-157 in the United States after the 2023 FDA action?

Not through the standard prescription-compounding pathway. The September 2023 Category 2 designation closed the 503A compounding channel, meaning licensed compounding pharmacies cannot prepare BPC-157 for individual patients under a physician's prescription. The 503B channel (outsourcing facilities that produce larger batches for healthcare providers) is also closed.

Physicians cannot write a legally fulfillable prescription for BPC-157 through a US-licensed compounding pharmacy following this date. Administration in a research context would require an IRB-approved protocol or, for a more formal investigational program, an FDA-regulated IND application. No active publicly registered IND for BPC-157 in humans is known as of 2025.

## Why does this site exist under a domain that references 'prescribed'?

The domain name bpc157prescribed.com reflects the compound's regulatory biography rather than a service this site offers. BPC-157 was, for a period before September 2023, accessible through the prescription-compounding system in the United States. The 2023 FDA action that closed that pathway is the central regulatory fact that readers searching 'BPC-157 prescribed' most often want to understand. This site is an independent editorial publisher — it curates and summarizes the peer-reviewed research literature and regulatory record; it does not prescribe, compound, sell, or facilitate access to BPC-157 in any form. The /about page describes the publisher entity in full.

## What is the current clinical trial status of BPC-157?

As of 2025, the ClinicalTrials.gov registry shows limited registrations for BPC-157 as an intervention. The Pliva Phase 2 ulcerative colitis trial (PL 14736) was the most structured clinical evaluation and was completed — results showed favorable safety but were not comprehensively published in peer-reviewed literature [14]. No Phase 3 trials have been conducted. No active, publicly registered IND for BPC-157 in humans is known as of 2025. The compound remains at an early clinical stage despite three decades of preclinical research.

---

A curated reading of the peer-reviewed literature — not a clinic, not a vendor, not a recommendation.